Meghan Trainor Reveals Mounjaro Use for Weight Loss, Expresses Frustration Over Focus on Body Instead of Music

Meghan Trainor has disclosed her use of the type 2 diabetes medication Mounjaro, a semaglutide injection, as part of her weight loss journey over the past year.
The 31-year-old artist shared the news in an Instagram post on Monday, attributing the medication to helping her achieve the “healthiest, strongest version” of herself for her children and personal well-being.
Trainor, mother of sons Riley and Barry with husband Daryl Sabara, stated that her health journey included consulting a dietician, making lifestyle adjustments, and engaging in exercise with a trainer.
She emphasized that science and support were crucial factors in her transformation.
However, Trainor expressed disappointment over the public’s tendency to focus on her physical appearance rather than her music and dedication.
In this regard, she wrote, “It’s disheartening that so many of the inquiries were centered on my physique instead of my passion and the decade of hard work that brought me here. This is the reality of being a woman in the music industry.”
Furthermore, the “Whoops” singer, who previously managed gestational diabetes during her pregnancies, showcased her slimmer figure at the Billboard Women in Music event on Saturday, where she received a Hitmaker award.
Trainor concluded her post by advocating for discussions that prioritize talent and personal development over body image, stating, “Here’s to celebrating talent, growth, and the power of prioritizing yourself. Let’s continue to shift the conversation towards what truly matters.”
Additionally, the singer’s use of semaglutide underscores the growing trend among celebrities using GLP-1 medications for weight management, despite the long-term effects remaining unclear, as reported by the Daily Mail.